Methimazole is a thiourea antithyroid drug that’s acts by blocking the production of thyroid hormones. It is used in the management of hyperthyroidism including the treatment of Graves’ disease, the preparation of hyperthyroid patients for thyroid removal, use as an adjunct to radio-iodine therapy and the treatment of thyroid storm. Methimazole is a thyroid hormone synthesis inhibitor, but it does not inactivate the existing thyroxine and triiodothyronine stored in the thyroid or in the blood. Inhibition of thyroid hormone formation occurs by interfering with the incorporation of iodine into organic form by interfering with oxidation of the iodide ion through peroxidase activity
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Methimazole, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.